SCHEMBL16455221

SCHEMBL16455221

CC(O)[C@H](N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](C)C(N)=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSL P07711 1/20 0.49
FCER2 P06734 2/20 0.47
MMP1 P03956 1/20 0.47
GHSR Q92847 1/20 0.47
ACE P12821 1/20 0.47
GNPAT O15228 1/20 0.46
MMP9 P14780 1/20 0.46
MMP8 P22894 1/20 0.46
MMP14 P50281 1/20 0.46
OPRD1 P41143 2/20 0.46
OPRM1 P35372 1/20 0.46
OPRK1 P41145 1/20 0.46
PSMB5 P28074 4/20 0.46
BACE1 P56817 2/20 0.45
ALDH1A1 P00352 1/20 0.45
THRB P10828 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
HSD17B10 Q99714 1/20 0.45
HDAC3 O15379 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30561493 0.91 LTA4H (0.54) ACEGNPAT
SCHEMBL30530869 0.89 LTA4H (0.52) ACEGNPATBACE1
SCHEMBL30735528 0.88 MME (0.57) ACEGNPAT
SCHEMBL29877007 0.86 MME (0.55) ACEBACE1
SCHEMBL8018436 0.85 MMP1 (0.57) FCER2MMP1MMP9MMP8
SCHEMBL8018430 0.85 MMP1 (0.57) FCER2MMP1MMP9MMP8
SCHEMBL31174325 0.85 MME (0.60) ACE
SCHEMBL233444 0.85 MME (0.60) ACE
SCHEMBL233445 0.85 MME (0.60) ACE
SCHEMBL1864186 0.85 MME (0.60) ACE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10421954-B2 Hybrid polymers, pharmaceutical compositions and methods of synthesizing the same NEW YORK UNIVERSITY (US) 2019-09-24 US disclosed
US-20170015991-A1 HYBRID POLYMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF SYNTHESIZING THE SAME NEW YORK UNIVERSITY 2017-01-19 US disclosed
US-9458449-B2 Hybrid polymers, pharmaceutical compositions and methods of synthesizing the same NEW YORK UNIVERSITY (US) 2016-10-04 US disclosed
US-20150044189-A1 HYBRID POLYMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF SYNTHESIZING THE SAME NEW YORK UNIVERSITY 2015-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10421954-B2 Hybrid polymers, pharmaceutical compositions and methods of synthesizing the same F12, RPS4Y1, NPY1R CTSL 2483/4885FCER2 4248/4885MMP1 4169/4885
US-20170015991-A1 HYBRID POLYMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF SYNTHESIZING THE SAME F12, RPS4Y1, NPY1R CTSL 2483/4885FCER2 4248/4885MMP1 4169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.